Aequus Pharmaceuticals Receives Conditional Approval to Commence Trading on TSX-V Exchange

VANCOUVER, March 11, 2015 /CNW/ - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") is pleased to announce that the Company has received conditional approval for its common shares to be listed and commence trading on the TSX Venture Exchange ("TSX-V"). Subject to satisfying certain final approval requirements of the TSX-V, the Company anticipates that its common shares will commence trading on the TSX-V approximately one week from the date of this release under the trading symbol "AQS".

"We are delighted to have received this conditional approval," said Doug Janzen, CEO and President of Aequus. "Achieving a TSX-V listing is one component of our overall strategy, broadening our access to capital while providing liquidity for our investors. Over the next few months, we plan on advancing our lead program into clinic and rapidly expanding our development pipeline."

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. is a Vancouver-based specialty pharmaceutical company focused on enhancing delivery methods for approved drugs and select consumer products that are limited by non-compliance, high frequency dosing, first-pass metabolism side-effects, painful injections, or where the therapeutic profile can be improved by making a long-acting alternative available. 

Forward-Looking Statement Disclaimer

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the implementation of our business model and strategic plans; our ability to access capital; the intention to complete the listing of the common shares of the Company on the TSX-V.

Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to general business and economic conditions and the availability of financing on reasonable terms.

In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading "Risk Factors" in the Company's long-form prospectus dated February 18, 2015, a copy of which is available on Aequus' profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus' SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain.  Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

SOURCE Aequus Pharmaceuticals Inc.

Image with caption: "Aequus Pharmaceuticals Inc. (CNW Group/Aequus Pharmaceuticals Inc.)". Image available at: http://photos.newswire.ca/images/download/20150311_C4484_PHOTO_EN_13060.jpg

For further information: Contact Information: Aequus Investor Relations, Email: investors@aequuspharma.ca, Phone: 604-336-7906

RELATED LINKS
www.aequuspharma.ca

Organization Profile

Aequus Pharmaceuticals Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890